Evaluation of the Concentration of Ubiquitin C Protein (UBC) in Patients of Lung Cancer and Comparing with Healthy Subjects | ||
| Engineering and Technology Journal | ||
| Article 3, Volume 38, 2B, July 2020, Pages 61-65 PDF (671.89 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.30684/etj.v38i2B.449 | ||
| Authors | ||
| Abbas A. Mohammed* ; Saleen S. Abdulhadi | ||
| Department of Applied Science, University of Technology- Iraq. | ||
| Abstract | ||
| Ubiquitin protein has a conserved amino acid sequence, found in all eukaryotes and it is important in many of cellular functions .The increase or decrease in the ubiquitin level lead to causing many diseases including cancer .The aim of this study is to measure the concentration of ubiquitin c protein in blood serum of lung cancer patients and healthy control subjects by using ELISA technique. The Mean ± SD for ubiquitin c protein was (7.51 ± 5.76) in blood serum of the normal healthy subject and Std. Error mean was (1.82). While the Mean ± SD was (10.99 ± 4.56 ) for ubiquitin c protein in serum of lung cancer patients and Std. Error mean was (1.44) .The results showed no statistically significance the P value ( 0.15) between the protein concentration in the serum of patients with lung cancer compared to the serum concentration of healthy normal subjects. | ||
| Keywords | ||
| Ubiquitin protein; ELISA technique; Lung Cancer; serum concentration | ||
| References | ||
|
[1] G. Goldstein, M. Scheid, U. Hammerling, D. Schlesinger, H. Niall and E. Boyse, “Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 72,No. 1, 11–5, 1975. [2] R. Sujashvili, “Advantages of extracellular ubiquitin in modulation of immune responses,” Mediators of Inflammation, 4190390, 2016. [3] N. Swatek and D. Komander, “Ubiquitin modifications,” Cell Research, 26, 4, 399–422, 2016. [4] L. Herhaus, and I. Dikic, “Expanding the ubiquitin code through post-translational modification,” EMBO reports, 16, 9, 1071-83, 2015. [5] M. Mansour, “Ubiquitination: Friend and foe in cancer,” Int. J. Biochem. Cell Biol. 2018; 101, 80–93, 2018. [6] J. Harrigan, X. Jacq, N. Martin, S. Jackson, “Deubiquitylating enzymes and drug discovery: Emerging opportunities,” Nat. Rev. Drug Discovery, 2018, 17, 57–78, 2018. [7] S. Sane, and K. Rezvani, “Essential roles of E3 ubiquitin ligases in p53 regulation,” International Journal of Molecular Sciences, 18, 2, 442, 2017. [8] K. Takada, H. Nasu, N. Hibi, Y. Tsukada, K. Ohkawa, M. Fujimuro, H. Yokosawa, “Immunoassay for the quantification of intracellular multi-ubiquitin chains,” European Journal of Biochemistry, 233, 1, 42–47, 1995. [9] S. Rossi, C. Gesualdo, R. Maisto, C. Trotta, N. Di Carluccio, A. Brigida, C. Di Filippo, “High levels of serum ubiquitin and proteasome in a case of HLA-B27 uveitis,” International journal of molecular sciences, 18, 3, 505, 2017. [10] J. Salazar, “Overview of urea and creatinine,” Laboratory Medicine, Vol. 45, Issue 1, e19–e20, 2014. [11] E .Torres da Costa, V .Silva, E. C. Costalonga, F. O .Coelho, R. A. Caires, E. A. Burdmann, “Assessment of kidney function in patients with cancer,” Adv Chronic Kidney Dis. 25, 1, 49–56, 2018. [12] M. Okada, S. Miyazaki, Y. Hirasawa, “Increase in plasma concentration of ubiquitin in dialysis patients: possible involvement in β2-microglobulin amyloidosis,” Clin Chim Acta. 220, 135-144, 1993. [13] Y. Tang, Y. Geng, J. Luo, W. Shen, W. Zhu, C. Meng, M. Li, X. Zhou, S. Zhang, J. Cao, “Downregulation of ubiquitin inhibits the proliferation and radio resistance of non-small cell lung cancer cells in vitro and in vivo,” Scientific reports, 5, 9476, 2015. [14] C. Oh, S. Park, K. Lee, and J. Yoo, “Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention,” Scientific reports, 3, 2623, 2013. [15] L. Haakonsen, and M. Rape, “Ubiquitin levels: the next target against gynecological cancers?,” The Journal of clinical investigation, 127, 12, 4228–4230, 2017. [16] Y. Liu, Z. Yang, F. Du, Q. Yang, J. Hou and H. Wang, “Molecular mechanisms of pathogenesis in hepatocellular carcinoma revealed by RNA sequencing,” Molecular Medicine Reports, 16, 5, 6674–6682, 2017. [17] D. Hoeller, I. Dikic, “Targeting the ubiquitin system in cancer therapy,” Nature. 458, 7237, 438–444, 2009. [18] W. Ma, H. Kantarjian, X. Zhang, X. Wang, Z. Estrov, S. O'Brien and M. Albitar, “Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance,” Leukemia Res., 35, 4, 526-33, 2010. | ||
|
Statistics Article View: 242 PDF Download: 170 |
||